Company intelligence / Profile preview

Avril Biopharma

Oakland, California, United Statesavrilbiopharma.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Avril Biopharma has developed prototype candidates for rabies and influenza vaccines as well as human serum proteins using its egg-based recombinant production technology. The company is pre-clinical and seeking partners for further development of COVID‑19 vaccines and other products.

Therapeutic areas: HematologyRare DiseasesInfectious Diseases
Modalities: Recombinant proteinVaccineGene therapyEnzyme replacement therapyMonoclonal antibody (biosimilar)Antibody (therapeutic/diagnostic)
Industry: Biotech

Partnerships

Animal and Water Research Institutes at the Council for Scientific & Industrial Research (CSIR), Accra, Ghana

Beyond the preview

Go deeper on Avril Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Avril Biopharma.

Explore the full profile